Introduction Previously, we reported the frequency of epidermal growth factor receptor
(EGFR) and KRAS mutations in nonsmall-cell lung cancer (NSCLC) patients in Latin …

Introduction Frequency of mutations in EGFR and KRAS in non-small cell lung cancer
(NSCLC) is different between ethnic groups; however, there is no information in Latin …

Objectives Owing to novel therapy strategies in epidermal growth factor receptor (EGFR)-
mutated patients, molecular analysis of the EGFR and KRAS genome has become crucial …

Introduction: The detection of mutations in the epidermal growth factor receptor (EGFR)
gene, which predict sensitivity to treatment with EGFR tyrosine kinase inhibitors, represents …

Purpose Previous studies in non–small-cell lung cancer (NSCLC) have demonstrated a
wide variation in responsiveness to epidermal growth factor receptor (EGFR)–targeting …

Background Frequencies of EGFR and KRAS mutations in non-small cell lung cancer
(NSCLC) have predominantly been determined in East Asian and North American …

Introduction Mutations in EGFR and KRAS can impact treatment decisions for patients with
NSCLC. The incidence of these mutations varies, and it is unclear whether there is a …

Objectives Estimate the epidermal growth factor receptor (EGFR) mutation prevalence in all
non-small cell lung cancer (NSCLC) patients and patient subgroups. Results A total of 456 …

Lung cancer is the deadliest cancer worldwide. The mutational frequency of EGFR and
KRAS genes in lung adenocarcinoma varies worldwide per ethnicity and smoking. The …

BACKGROUND: The aim of this study was to validate clinical utilization of routinely prepared
cytology specimens for molecular testing to detect EGFR or KRAS mutations in lung cancer …